Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Airway management in thoracic surgery in a patient with right tracheal supernumerary bronchus.

Revista espanola de anestesiologia y reanimacion·2025
Same author

Correction: Improving time-resolution and sensitivity of <i>in situ</i> X-ray photoelectron spectroscopy of a powder catalyst by modulated excitation.

Chemical science·2023
Same author

Improving time-resolution and sensitivity of <i>in situ</i> X-ray photoelectron spectroscopy of a powder catalyst by modulated excitation.

Chemical science·2023
Same author

Evaluating the effectiveness of a single-day simulation-based program in psychiatry for medical students: a controlled study.

BMC medical education·2021
Same author

Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories.

Journal of clinical microbiology·2020
Same author

Self-expanding metallic Y-stent compared to silicone Y-stent for malignant lesions of the main carina: A single center retrospective study.

Respiratory medicine and research·2020

Related Experiment Video

Updated: Jun 7, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Vitronectin inhibits blood platelet aggregation.

M Røger1, K Høgåsen, N O Solum

  • 1Institute of Pathology Rikshospitalet, N-0027, Oslo, Norway.

Platelets
|November 4, 2010
PubMed
Summary
This summary is machine-generated.

Vitronectin inhibits platelet aggregation, a process crucial for blood clotting. This study reveals vitronectin

More Related Videos

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 7, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Area of Science:

  • Biochemistry and cell biology
  • Hematology and thrombosis

Background:

  • Platelet aggregation is a critical process in hemostasis and thrombosis.
  • Adhesive proteins like fibrinogen, fibronectin, and von Willebrand factor play key roles in platelet function.
  • Vitronectin is an adhesive protein found in plasma and extracellular matrix, but its role in platelet aggregation is not fully understood.

Purpose of the Study:

  • To investigate the effect of vitronectin on platelet aggregation.
  • To elucidate the mechanism by which vitronectin influences platelet aggregation.

Main Methods:

  • Platelet aggregation assays were performed using thrombin and ADP as agonists.
  • Dose-response effects of vitronectin on platelet aggregation were evaluated.
  • The impact of a monoclonal antibody (MoAb) to vitronectin on thrombin-induced platelet aggregation was assessed.
  • The role of the platelet Fc-receptor was investigated in relation to the MoAb's effect.

Main Results:

  • Vitronectin demonstrated a dose-dependent inhibition of both thrombin- and ADP-induced platelet aggregation.
  • A monoclonal antibody targeting vitronectin enhanced thrombin-induced platelet aggregation.
  • The enhancing effect of the MoAb was independent of the platelet Fc-receptor, suggesting direct interaction with vitronectin.
  • Vitronectin contains the Arg-Gly-Asp (RGD) sequence, known to bind to platelet glycoprotein complex IIb/IIIa (GPIIb/IIIa).

Conclusions:

  • Vitronectin inhibits platelet aggregation by interfering with fibrinogen binding to GPIIb/IIIa on activated platelets.
  • The RGD sequence in vitronectin is likely involved in its interaction with GPIIb/IIIa.
  • Vitronectin modulates fibrinogen's pro-aggregatory function, suggesting a regulatory role in thrombosis.